AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3754233 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 400 mg bd
Number of subjects: 8
Study 3754233 — intervention group
Group type: COMPARATOR
Intervention: Pirenzepine 50 mg bd
Number of subjects: 8
Study 3754233 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg bd + Pirenzepine 25 mg bd
Number of subjects: 8
Study 3754233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 29562613 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Glycemic Index Diet (LGI)
Number of subjects: 21
Study 29562613 — intervention group
Group type: COMPARATOR
Intervention: Moderate Glycemic Index Diet (MGI)
Number of subjects: 21
Study 27342387 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic dose of tedizolid phosphate (200mg)
Number of subjects: 48
Study 27342387 — intervention group
Group type: EXPERIMENTAL
Intervention: Supratherapeutic dose of tedizolid phosphate (1200mg)
Number of subjects: 48
Study 27342387 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (positive control)
Number of subjects: 48
Study 27342387 — intervention group
Group type: COMPARATOR
Intervention: Placebo (negative control)
Number of subjects: 48
Study 23591951 — intervention group
Group type: EXPERIMENTAL
Intervention: Parallel squat with 80% 1 repetition maximum without vibration (NV‐PS)
Number of subjects: 15
Study 23591951 — intervention group
Group type: EXPERIMENTAL
Intervention: Parallel squat with 80% 1 repetition maximum on a whole body vibration platform (WBV‐PS)
Number of subjects: 15
Study 23591951 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 15
Study 22429308 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based health risk assessment with individually-tailored feedback
Number of subjects: 0
Study 22429308 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 0
Study 20019625 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic bands
Number of subjects: 50
Study 20019625 — intervention group
Group type: COMPARATOR
Intervention: Weights
Number of subjects: 50
Study 20019625 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 50
Study 18682410 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ml ropivacaine 0.5%
Number of subjects: 40
Study 18682410 — intervention group
Group type: COMPARATOR
Intervention: 20 ml ropivacaine 0.5%
Number of subjects: 40
Study 15591298 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT users
Number of subjects: 48
Study 15591298 — intervention group
Group type: EXPERIMENTAL
Intervention: Fit groups
Number of subjects: 48
Study 15591298 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT users and fit groups
Number of subjects: 48
Study 15591298 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 48
Study 15591298 — intervention group
Group type: COMPARATOR
Intervention: Physically fit women
Number of subjects: 48
Study 15591298 — intervention group
Group type: COMPARATOR
Intervention: Fitness
Number of subjects: 48
Study 12616317 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-segment algorithm (tau = 250 ms)
Number of subjects: 104
Study 12616317 — intervention group
Group type: COMPARATOR
Intervention: 2-segment fixed end algorithm (tau = 125-250 ms)
Number of subjects: 104
Study 12616317 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-segment fixed start algorithm (tau = 105-210 ms)
Number of subjects: 104
Study 12616317 — intervention group
Group type: COMPARATOR
Intervention: Single-segment algorithm (tau = 210 ms)
Number of subjects: 104
Study 12516414 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 25 mg three times a day for 7 days with tegafur 200 mg three times a day (Group I, n = 11)
Number of subjects: 21
Study 12516414 — intervention group
Group type: COMPARATOR
Intervention: Tegafur 200 mg three times a day without indomethacin (Group II, n = 10)
Number of subjects: 21
Study 9098853 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (10 mg/kg after meeting criteria and before cannulation, plus a 20 mg/kg priming dose to the ECMO circuit)
Number of subjects: 25
Study 8210924 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac (300 mg b.i.d.)
Number of subjects: 1289
Study 8210924 — intervention group
Group type: COMPARATOR
Intervention: Active-reference preparations (including piroxicam, naproxen, indomethacin, indomethacin SR, diclofenac SR)
Number of subjects: 1289
Study 8210924 — intervention group
Group type: COMPARATOR
Intervention: Active-reference preparations and placebos
Number of subjects: 1289
Study 3093661 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact milk formula
Number of subjects: 20
Study 3093661 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose-free preparation
Number of subjects: 20
Study 31393746 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-guided thermal ablation with an EM navigation system
Number of subjects: 40
Study 31393746 — intervention group
Group type: COMPARATOR
Intervention: Conventional CT-guided thermal ablation
Number of subjects: 40
Study 30287661 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year financial support program for education
Number of subjects: 0
Study 30287661 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 28514624 — intervention group
Group type: EXPERIMENTAL
Intervention: Evacetrapib (130 mg daily)
Number of subjects: 12092
Study 28514624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12092
Study 28514624 — intervention group
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Number of subjects: 12092
Study 26143106 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed plus carboplatin
Number of subjects: 0
Study 26143106 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed alone
Number of subjects: 0
Study 23135693 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg tropisetron alone (T)
Number of subjects: 224
Study 23135693 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg tropisetron and 8 mg dexamethasone (TD)
Number of subjects: 224
Study 23135693 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg tropisetron and 40 mg methylprednisolone (TM)
Number of subjects: 224
Study 21542721 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (300,000 IU/month intramuscular injection for 6 months)
Number of subjects: 62
Study 21542721 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intramuscular injection for 6 months)
Number of subjects: 62
Study 21542721 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Number of subjects: 62
Study 18498678 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 200 mcg once-daily for 8 days
Number of subjects: 59
Study 18498678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 17205817 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-step sequential method (TSSM) plus inhalation of Pulmicort Turbuhaler 200 microg, twice a day
Number of subjects: 40
Study 17205817 — intervention group
Group type: COMPARATOR
Intervention: Pulmicort Turbuhaler alone
Number of subjects: 40
Study 17205817 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (TSSM and control)
Number of subjects: 40
Study 15058750 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine-Purite 0.15%
Number of subjects: 20
Study 15058750 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine-Purite 0.15% (first)
Number of subjects: 20
Study 15058750 — intervention group
Group type: COMPARATOR
Intervention: Brimonidine tartrate 0.2% (first)
Number of subjects: 20
Study 10966540 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric cardioversion (n = 11)
Number of subjects: 35
Study 10966540 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic cardioversion (n = 24)
Number of subjects: 35
Study 10966540 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 70)
Number of subjects: 35
Study 8694043 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol every 3 hours (maximum of 8 doses)
Number of subjects: 522
Study 8694043 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol every 6 hours (maximum of 4 doses)
Number of subjects: 522
Study 8694043 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol every 6 hours
Number of subjects: 522
Study 8694043 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol every 3 hours
Number of subjects: 522
Study 8694043 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 522
Study 1713484 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine aspartate (AA)
Number of subjects: 11
Study 1713484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 6815664 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate ('Priadel')
Number of subjects: 5
Study 6815664 — intervention group
Group type: COMPARATOR
Intervention: Lithium citrate ('Litarex')
Number of subjects: 5
Study 31725942 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 10 mg
Number of subjects: 489
Study 31725942 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 20 mg
Number of subjects: 489
Study 31725942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 489
Study 31050355 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab plus bendamustine
Number of subjects: 0
Study 31050355 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Number of subjects: 0
Study 31050355 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 27696720 — intervention group
Group type: COMPARATOR
Intervention: FeFol (iron and folic acid tablet)
Number of subjects: 620
Study 27696720 — intervention group
Group type: EXPERIMENTAL
Intervention: MMN (multiple-micronutrients tablet)
Number of subjects: 620
Study 27696720 — intervention group
Group type: EXPERIMENTAL
Intervention: PE (protein-energy lipid-based nutritional supplement)
Number of subjects: 620
Study 27696720 — intervention group
Group type: EXPERIMENTAL
Intervention: PE + MMN (protein-energy + multiple-micronutrients lipid-based nutritional supplement)
Number of subjects: 620
Study 27696720 — intervention group
Group type: EXPERIMENTAL
Intervention: PE + MMN
Number of subjects: 620
Study 25837705 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone administration (2 mg/kg testosterone enanthate monthly for two months before surgery)
Number of subjects: 182
Study 23389112 — intervention group
Group type: EXPERIMENTAL
Intervention: High fiber (HF) diet
Number of subjects: 25
Study 23389112 — intervention group
Group type: COMPARATOR
Intervention: Low fiber (LF) diet
Number of subjects: 25
Study 22941976 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma risk registers intervention with electronic alerts and practice-based training
Number of subjects: 911
Study 22941976 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine care)
Number of subjects: 911
Study 20023343 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle energy technique (MET) group, n=15
Number of subjects: 30
Study 20023343 — intervention group
Group type: COMPARATOR
Intervention: Static stretch group (controls), n=15
Number of subjects: 30
Study 17540191 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-administered tailored behavioral intervention
Number of subjects: 600
Study 17540191 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-administered medication management
Number of subjects: 600
Study 17540191 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tailored behavioral intervention and medication management
Number of subjects: 600
Study 17540191 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 600
Study 15510946 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (after the cord stopped pulsating)
Number of subjects: 104
Study 15510946 — intervention group
Group type: COMPARATOR
Intervention: Early cord clamping (within 10s after delivery)
Number of subjects: 104
Study 11451215 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (OM) 10 mg once daily
Number of subjects: 0
Study 11451215 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50 mg once daily
Number of subjects: 0
Study 9649062 — intervention group
Group type: EXPERIMENTAL
Intervention: ET0-sterilized low-flux polysulphone membranes (F6)
Number of subjects: 6
Study 9649062 — intervention group
Group type: EXPERIMENTAL
Intervention: Steam-sterilized polysulphone membranes (F6-HPS)
Number of subjects: 6
Study 9649062 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching back to ETO-sterilized membranes (F6)
Number of subjects: 6
Study 7747848 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (median dose 3.1 mg.kg‐1)
Number of subjects: 23
Study 7747848 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone (median dose 6.0 mg.kg‐1)
Number of subjects: 23
Study 7747848 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid 10% 0.3 ml.kg‐1
Number of subjects: 23
Study 2204553 — intervention group
Group type: EXPERIMENTAL
Intervention: LH-kit cycles (1 insemination)
Number of subjects: 60
Study 2204553 — intervention group
Group type: COMPARATOR
Intervention: Non-LH method cycles (2 alternate day inseminations)
Number of subjects: 60
Study 299451 — intervention group
Group type: EXPERIMENTAL
Intervention: butorphanol/acetaminophen
Number of subjects: 104
Study 299451 — intervention group
Group type: EXPERIMENTAL
Intervention: oxycodone/acetaminophen
Number of subjects: 104
Study 299451 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 104
Study 31594200 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Laser Therapy (HILT)
Number of subjects: 40
Study 31594200 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Number of subjects: 40
Study 31509332 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother-Child Education Program (MOCEP)
Number of subjects: 0
Study 31509332 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation evaluation
Number of subjects: 0
Study 28376743 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 μg FLU-v in saline (arm 1)
Number of subjects: 222
Study 28376743 — intervention group
Group type: EXPERIMENTAL
Intervention: Emulsified 500 μg FLU-v in Montanide ISA-51 and WFI followed by one saline dose (arm 2)
Number of subjects: 222
Study 28376743 — intervention group
Group type: EXPERIMENTAL
Intervention: Montanide ISA-51 and WFI emulsion followed by one saline dose (arm 4)
Number of subjects: 222
Study 28376743 — intervention group
Group type: COMPARATOR
Intervention: Two saline doses (arm 3)
Number of subjects: 222
Study 25983095 — intervention group
Group type: EXPERIMENTAL
Intervention: CCRT with docetaxel and capecitabine
Number of subjects: 81
Study 25983095 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy with docetaxel and capecitabine
Number of subjects: 81
Study 24417600 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisystemic Therapy (MST)
Number of subjects: 129
Study 24417600 — intervention group
Group type: COMPARATOR
Intervention: Individual Therapy (IT)
Number of subjects: 129
Study 22137191 — intervention group
Group type: EXPERIMENTAL
Intervention: PermaNet 2.0 (Vestergaard‐Frandsen, Denmark)
Number of subjects: 0
Study 20631375 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim 500 μg
Number of subjects: 40
Study 20631375 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim 750 μg
Number of subjects: 40
Study 20631375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 17952697 — intervention group
Group type: EXPERIMENTAL
Intervention: Water exercise once-weekly for 24 weeks
Number of subjects: 30
Study 17952697 — intervention group
Group type: EXPERIMENTAL
Intervention: Water exercise twice-weekly for 24 weeks
Number of subjects: 30
Study 17952697 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 30
Study 15602503 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine (5 mg/70 kg, intravenous)
Number of subjects: 0
Study 15602503 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine+cocaine (combination)
Number of subjects: 0
Study 15602503 — intervention group
Group type: COMPARATOR
Intervention: Cocaine (0.2 mg/kg, intravenous)
Number of subjects: 0
Study 12670118 — intervention group
Group type: EXPERIMENTAL
Intervention: HBO2 therapy
Number of subjects: 24
Study 12670118 — intervention group
Group type: EXPERIMENTAL
Intervention: HBO2 + Scaling
Number of subjects: 24
Study 12670118 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling
Number of subjects: 24
Study 12670118 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study 10611552 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh egg and cow's milk powder
Number of subjects: 50
Study 10611552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 7700752 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP and PRP-T in one injection (Group 1)
Number of subjects: 150
Study 7700752 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP and PRP-T separately (Group 2)
Number of subjects: 150
Study 7700752 — intervention group
Group type: COMPARATOR
Intervention: DTP and HbOC separately (Group 3)
Number of subjects: 150
Study 2505632 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil 1.0 mg
Number of subjects: 6
Study 2505632 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil 4 mg
Number of subjects: 6
Study 2505632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 1107233 — intervention group
Group type: EXPERIMENTAL
Intervention: Fraction A
Number of subjects: 131
Study 1107233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 31415571 — intervention group
Group type: EXPERIMENTAL
Intervention: Invitation to commit to becoming better prepared for floods
Number of subjects: 774
Study 31415571 — intervention group
Group type: COMPARATOR
Intervention: No commitment invitation (control group)
Number of subjects: 774
Study 29187413 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane-based inhalational anaesthesia
Number of subjects: 1200
Study 29187413 — intervention group
Group type: COMPARATOR
Intervention: Propofol-based intravenous anaesthesia
Number of subjects: 1200
Study 24824770 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate treatment + 6‐wk exercise (sports‐ADHD)
Number of subjects: 35
Study 24824770 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate treatment + 6‐wk education (edu‐ADHD)
Number of subjects: 35
Study 23463297 — intervention group
Group type: EXPERIMENTAL
Intervention: St. John's Wort (SJW) 300 mg × 3/day for 2 weeks after PCI
Number of subjects: 23
Study 23463297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 23463297 — intervention group
Group type: EXPERIMENTAL
Intervention: St. John's Wort (SJW)
Number of subjects: 23
Study 21228120 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-particle abrasion (APA) with 25 μm Al(2)O(3)
Number of subjects: 60
Study 21228120 — intervention group
Group type: EXPERIMENTAL
Intervention: Silica coating with 30 μm Al(2)O(3) particles modified by silica
Number of subjects: 60
Study 21228120 — intervention group
Group type: EXPERIMENTAL
Intervention: Silica coating
Number of subjects: 60
Study 20078381 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.075% retinol cream
Number of subjects: 57
Study 20078381 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 57
Study 20078381 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.04% retinol cream
Number of subjects: 57
Study 16278692 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate juice (PJ) supplementation (400 ml daily for 5 weeks)
Number of subjects: 30
Study 16278692 — intervention group
Group type: COMPARATOR
Intervention: Placebo (synthetic orange‐flavoured drink, 400 ml daily for 5 weeks)
Number of subjects: 30
Study 15519498 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 21
Study 15519498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 11481130 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine-Alone
Number of subjects: 102
Study 11481130 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive/Behavioral Therapy-Alone (CBT)
Number of subjects: 102
Study 11481130 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined (Desipramine + CBT)
Number of subjects: 102
Study 9233238 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of essential fatty acids (EFA) - 20 ml solution A (1.6 gr EFA with linoleic acid, 112 UI vitamin A, 5 UI Vitamin E) applied every 8 hours for 21 days
Number of subjects: 86
Study 9233238 — intervention group
Group type: COMPARATOR
Intervention: Topical application of mineral oil - 20 ml solution B (1.6 gr mineral oil, 112 UI Vitamin A, 5 UI Vitamin E) applied every 8 hours for 21 days
Number of subjects: 86
Study 7596115 — intervention group
Group type: EXPERIMENTAL
Intervention: Signal uncertainty (randomly at 501 or 2818 Hz)
Number of subjects: 0
Study 7596115 — intervention group
Group type: EXPERIMENTAL
Intervention: Masker uncertainty (random-frequency, random-level tonal distracters)
Number of subjects: 0
Study 2590807 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 0
Study 2590807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 5320590 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic chlorpromazine (CPZ) administration
Number of subjects: 0
Study 5320590 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 30753377 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of azathioprine with adalimumab
Number of subjects: 0
Study 30753377 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab monotherapy
Number of subjects: 0
Study 28650784 — intervention group
Group type: EXPERIMENTAL
Intervention: Papacarie Duo
Number of subjects: 20
Study 28650784 — intervention group
Group type: EXPERIMENTAL
Intervention: Carie Care
Number of subjects: 20
Study 25887060 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental imagery
Number of subjects: 30
Study 23128963 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibuprofen 10 mg/kg within 12‐24 h after birth followed by 5 mg/kg at 24 and 48 h
Number of subjects: 36